非小细胞肺癌患者血清CYFRA_(21-1)和CEA的临床应用

Clinical Measurement and Evaluation of CYFRA_(21-1) and CEA for Non Small Cell Cancer

摘要: 目的　研究癌标CYFRA2 1 1及CEA对非小细胞肺癌 (NSCLC)诊断、病情及预后的临床应用价值。方法　用放射免疫法检测 10 1例NSCLC患者和 112例良性肺疾病患者血清CYFRA2 1 1和CEA, 比较NSCLC的不同组织类型、临床分期、手术前后差异。结果　CYFRA2 1 1对NSCLC诊断敏感性、特异性、有效性为 72 .4 %、87.3%、79.1%, CYFRA2 1 1对鳞癌诊断敏感性、有效性高于腺癌 (P <0 .0 5 ), 而CEA对NSCLC诊断敏感性、特异性、有效性为 4 7.5 %、94 .0 %、71.6 %, CEA对腺癌诊断敏感性、有效性高于鳞癌 (P <0 .0 1), CYFRA2 1 1与CEA联合应用可提高对NSCLC诊断敏感性、有效性。血清CYFRA2 1 1水平与TNM分期有关, 随病情变化而改变。结论　血清CYFRA2 1 1检测特别是与CEA联合应用对NSCLC患者诊断、病情监测、预后判断有较高临床应用价值。

Abstract: Objective This study tried to investigute the effect of serum CYFRA 21 1 as a new lung cancer marker, with CEA, in clinical dignosis and monitoring the prognosis of non small cell lung cancer (NSCLC). Methods The serum levels of CYFRA 21 1 and CEA in 101 patients with NSCLC and 112 patients with benign lung disaeses(BLD) were measured by radioimmunoassay.Serum CYFRA 21 1 and CEA were compared between different histological types, Clinical stages; before and after operation. Results The sensi...